ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Vogelzang Discusses the Cabozantinib Trial Design

Nicholas J. Vogelzang, MD
Published: Wednesday, Jul 20, 2011

Nicholas J. Vogelzang, MD, head of the Genitourinary Cancer Section at the Comprehensive Cancer Centers of Nevada discusses the 9 arm trial design for cabozantinib (XL184) in multiple disease types. Explaining that after 12 weeks of treatment the enrolled patients received scans and blood tests. If they benefited after 12 weeks they were allowed to stay on the drug. If they were stable they could either continue or discontinue using the drug. If the cancer was shown to be growing at anytime throughout the trial or if there was undue toxicity the patients were made to discontinue the trial.
Nicholas J. Vogelzang, MD, head of the Genitourinary Cancer Section at the Comprehensive Cancer Centers of Nevada discusses the 9 arm trial design for cabozantinib (XL184) in multiple disease types. Explaining that after 12 weeks of treatment the enrolled patients received scans and blood tests. If they benefited after 12 weeks they were allowed to stay on the drug. If they were stable they could either continue or discontinue using the drug. If the cancer was shown to be growing at anytime throughout the trial or if there was undue toxicity the patients were made to discontinue the trial.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x